Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal umbilical cord blood-derived NK cells for recurrent ovarian cancer
NL-OMON45699Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of aldesleukin in ovarian cancer (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Safety and toxicity. Started Jun 2019; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON45699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45699.